Deloitte July 31, 2020
Mark Lush, Christopher Zant, Sherilyn Notte Tuthill, Alicia Saddock

The life sciences industry is moving beyond core patient services to the next generation of engagement platforms that seamlessly span the entire patient life cycle to help improve health outcomes.

IN our 2016 article Patient engagement strategies in a digital environment, we described life sciences companies’ essential opportunity to make a meaningful impact on patients’ lives by engaging more closely with them.1 At that time, various technologies were being launched to help make patient engagement more holistic and seamless across the spectrum of emergent tools, including patient services platforms, wearable monitoring devices, mobile wellness apps, and the like.

Many life sciences companies were embarking on transforming their organizations, people, processes, and platforms to strengthen patient engagement with a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech
Aviv Regev: The Revolution in Digital Biology
Global Inequities In Access To Drugs Costs Millions Of Lives Each Year
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
Why Conflicts Of Interest May Not Be As Bad As You Think (And Besides We All Have Them!)

Share This Article